체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

teva pharma b.v., haarlem array - 16812 vÁpenatÁ sŮl rosuvastatinu - potahovaná tableta - 40mg - rosuvastatin

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 17420 sunitinib - tvrdá tobolka - 12,5mg - sunitinib

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 17420 sunitinib - tvrdá tobolka - 25mg - sunitinib

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 17420 sunitinib - tvrdá tobolka - 50mg - sunitinib

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 15618 teriflunomid - potahovaná tableta - 14mg - teriflunomid

유럽 연합 - 체코어 - EMA (European Medicines Agency)

taw pharma (ireland) limited - hydrochlorid klopidogrelu - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotické činidla - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 18095 kabazitaxel - koncentrát pro infuzní roztok - 20mg/ml - kabazitaxel

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 21421 agomelatin s kyselinou citronovou - potahovaná tableta - 25mg - agomelatin

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 17227 solifenacin-sukcinÁt - potahovaná tableta - 10mg - solifenacin

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 17227 solifenacin-sukcinÁt - potahovaná tableta - 5mg - solifenacin